William Blair reaffirmed their market perform rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...